Antihypertensive therapy: special focus on drug interactions

Area of Science:

• Pharmacology
• Geriatric Medicine
• Clinical Pharmacy

Background:

• Antihypertensive drug use is common in patients aged 55-65, approaching 60% lifetime risk.
• Hypertension control remains inadequate in most patients, with prevalence increasing with age.
• Older patients often have comorbidities and polypharmacy, raising risks for adverse drug reactions and interactions.

Purpose of the Study:

• To review common antihypertensive drug classes, focusing on pharmacodynamic and pharmacokinetic interactions.
• To highlight the evolving landscape of drug safety and the importance of ongoing safety assessments.
• To discuss the clinical relevance of drug interactions versus the risks of undertreated hypertension.

Main Methods:

• Review of major antihypertensive drug classes: diuretics, beta-blockers, ACE inhibitors, CCBs, ARBs, and alpha-blockers.
• Analysis of pharmacodynamic and pharmacokinetic drug interactions associated with these agents.
• Discussion of drug interactions involving cytochrome P450 metabolism.

Main Results:

• Multi-drug therapy, advanced age, and comorbidities are significant risk factors for adverse drug events.
• Clinically relevant drug interactions involving antihypertensives are a concern for many patients.
• The risk of inadequately treated hypertension may currently outweigh the risk of drug interactions for many patients.

Conclusions:

• Continuous evaluation of drug safety is essential due to the changing spectrum of prescribed medications.
• Balancing concerns about drug interactions with the need for therapeutic efficacy is critical in hypertension management.
• While drug interactions pose risks, undertreated hypertension presents a significant, potentially greater, clinical challenge.